Talecris Biotherapeutics (Nasdaq: TLCR) beat analysts’ expectations Wednesday for its latest quarter on profit at 45 cents per share.
However, overall revenue did come in slightly under the $409.6 million estimated by analysts in a Thomson Reuters survey at $406.7. Revenues were up 6.7 percent from a year ago, Talecris reported Wednesday after the markets closed.
The RTP-based company is still awaiting government approval for its proposed merger with Sapin-based Grifols.
“While we await approval from the U.S. Federal Trade Commission on the proposed merger of Talecris and Grifols, I am pleased with the organizational focus that ultimately drove our significant increase in net income during the first quarter,” said Lawrence Stern, Talecris’ chairman and chief executive officer, in a statement. ”This focus was evident in all functional areas of the organization.”
For the full earnings report, read here.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.
